Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism
26. mars 2012 oppdatert av: Abbott
A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.
Studieoversikt
Status
Fullført
Detaljert beskrivelse
The primary objective of this study is to evaluate the safety of Zemplar® in the treatment of Secondary hyperparathyroidism (iParathormone>300 pg/mL) in subjects on hemodialysis treated in conditions of usual clinical care.
The primary safety endpoints of this study are to evaluate the safety of Zemplar by recording the number of hospitalizations and days hospitalized.
A secondary efficacy endpoint will be the proportion of subjects achieving therapeutic success. Therapeutic success with Zemplar® will be defined as:
- 40% reduction in the base iPTH level is achieved, and/or;
- serum iParathormone level < 300 pg/mL.
Additional secondary endpoints are the incidence (proportion of patients) of clinically meaningful hypercalcemia (defined as corrected serum calcium (Ca) > 11.0 mg/dL taken at 2 consecutive measurements), hyperphosphatemia (defined as serum phosphorous (P)>6.5 mg/dL taken at 2 consecutive measurements), and elevated Ca x P product (defined as serum Ca x P>65 mg^2/dL^2 taken at 2 consecutive measurements). Safety also will be assessed through adverse event monitoring and evaluation of laboratory variables and vital signs.
Studietype
Observasjonsmessig
Registrering (Faktiske)
237
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Athens, Hellas, 11526
- Site Reference ID/Investigator# 32055
-
Athens, Hellas, 11528
- Site Reference ID/Investigator# 32050
-
Athens, Hellas, 11528
- Site Reference ID/Investigator# 32051
-
Athens, Hellas, 17237
- Site Reference ID/Investigator# 32049
-
Athens, Hellas
- Site Reference ID/Investigator# 5283
-
Chalkida, Hellas, 34100
- Site Reference ID/Investigator# 32056
-
Chania, Hellas, 73100
- Site Reference ID/Investigator# 32057
-
Drama, Hellas, 66100
- Site Reference ID/Investigator# 32058
-
Holargos, Hellas, 15562
- Site Reference ID/Investigator# 32077
-
Katerini, Hellas, 60100
- Site Reference ID/Investigator# 32076
-
Kavala, Hellas, 65201
- Site Reference ID/Investigator# 32059
-
Komotini, Hellas, 69100
- Site Reference ID/Investigator# 32053
-
Lamia, Hellas, 35100
- Site Reference ID/Investigator# 32060
-
Lefkada, Hellas, 31100
- Site Reference ID/Investigator# 32061
-
Livadia, Hellas, 32100
- Site Reference ID/Investigator# 32062
-
Pireus, Hellas
- Site Reference ID/Investigator# 32048
-
Preveza, Hellas, 48100
- Site Reference ID/Investigator# 32054
-
Ptolemaida, Hellas, 50200
- Site Reference ID/Investigator# 32063
-
Volos, Hellas, 38222
- Site Reference ID/Investigator# 32075
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Hemodialysis patients with secondary hyperparathyoidism treated with IV Paricalcitol according to the approved Summary of Product Characteristics
Beskrivelse
Inclusion Criteria:
- Subject is >= 18 years of age and diagnosed with secondary hyperparathyroidism and a pretreatment iParathormone > 300 pg/mL.
- Subject is receiving chronic hemodialysis.
- Subject for which treatment with Zemplar Injection is indicated clinically according to the criteria of participating investigator.
- Subject has provided their informed consent to participate.
Exclusion Criteria:
- Subject has a corrected serum calcium > 10.5 mg/dL, serum phosphorus >= 6.5 mg/dL or subjects with corrected Ca x P >= 65 mg^2/dl^2.
- Subject has known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients.
- Subject has participated in clinical study within the last month.
- Zemplar is contraindicated according to the Summary of Product Characteristics.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Chronic Kidney Disease
All eligible patients treated with IV Paricalcitol (Zemplar)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety Evaluation of Paricalcitol by Recording the Number of Hospitalizations
Tidsramme: Baseline to Month 24 Visit
|
The number of participants who were hospitalized during the study and the number of hospitalizations are summarized.
|
Baseline to Month 24 Visit
|
|
Safety Evaluation of Paricalcitol by Recording the Number of Days Hospitalized
Tidsramme: Baseline to Month 24 Visit
|
The mean (average) number of days hospitalized per participant for those hospitalized during the study.
|
Baseline to Month 24 Visit
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Proportion of Patients Achieving Therapeutic Success (Defined as 40% Reduction in Base Parathormone Level and/or Parathormone Level <300 pg/ml)
Tidsramme: Baseline to Month 24 Visit
|
Therapeutic success of paricalcitol treatment was defined as a 40% decrease from the baseline measurement in the level of intact parathyroid hormone (also known as iPTH or parathormone) and/or a serum intact parathyroid hormone level less than 300 picograms per milliliter (pg/mL) for at least 2 consecutive available measurements during the 24-month follow-up period.
|
Baseline to Month 24 Visit
|
|
The Incidence of Clinically Significant Hypercalcemia
Tidsramme: Baseline to Month 24 Visit
|
The number of participants with clinically significant hypercalcemia (too much calcium in the blood), defined as a corrected serum calcium level greater than 11.0 milligrams per deciliter (mg/dL) at 2 consecutive measurements.
|
Baseline to Month 24 Visit
|
|
The Incidence of Clinically Significant Hyperphosphatemia
Tidsramme: Baseline to Month 24 Visit
|
The number of participants with clinically significant hyperphosphatemia (too much phosphorous in the blood), defined as serum phosphorous levels greater than 6.5 milligrams per deciliter (mg/dL) at 2 consecutive measurements.
|
Baseline to Month 24 Visit
|
|
The Incidence of Clinically Significant Elevation of Calcium-phosphorous (Ca x P) Product
Tidsramme: Baseline to Month 24 Visit
|
The number of participants with clinically significant levels of calcium-phosphorous product (Ca x P), defined as serum calcium-phosphorous product levels greater than 65 milligrams squared per deciliters squared (mg^2/dL^2) at 2 consecutive measurements.
|
Baseline to Month 24 Visit
|
|
To Estimate the Incidence of (S)AEs/(S)ADRs
Tidsramme: Baseline to Month 24 Visit
|
The number of adverse events, serious adverse events (including death), adverse drug reactions, and serious adverse drug reactions experienced by participants during the study are summarized.
Adverse events include any events reported regardless of whether or not they were considered related to the study drug.
Adverse drug reactions include events where a causal relationship between the drug and the occurence of the event is suspected.
For additional details see the Reported Adverse Events section.
|
Baseline to Month 24 Visit
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studiestol: Konstantinos Xynos, MD, Abbott Laboratories Hellas S.A.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. desember 2006
Primær fullføring (Faktiske)
1. februar 2011
Studiet fullført (Faktiske)
1. februar 2011
Datoer for studieregistrering
Først innsendt
27. februar 2010
Først innsendt som oppfylte QC-kriteriene
4. mars 2010
Først lagt ut (Anslag)
5. mars 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
27. mars 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. mars 2012
Sist bekreftet
1. mars 2012
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P06-120
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sekundær hyperparathyroidisme
-
National Cancer Institute, EgyptFullførtBenneoplasma, ondartet vertebral kolonne Thoracic SecondaryEgypt